OverviewChartNewsTraderScreen

ALMIRALL S.A. EO -,12/  ES0157097017  /

Berlin
2024-05-07  8:06:46 AM Chg. -0.040 Volume Bid8:07:07 AM Ask8:07:07 AM High Low
8.525EUR -0.47% 0
Turnover: 0.000		 8.525Bid Size: 130 8.780Ask Size: 126 8.525 8.525
GlobeNewswire 04-16 Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
GlobeNewswire 03-13 Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermat...
GlobeNewswire 03-05 Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of...
GlobeNewswire 01-10 Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
GlobeNewswire 2023-11-14 Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
GlobeNewswire 2023-11-14 Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for de...
GlobeNewswire 2023-10-05 Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
GlobeNewswire 2023-09-21 Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
GlobeNewswire 2023-09-18 Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and No...
GlobeNewswire 2023-09-12 Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockh...
GlobeNewswire 2023-09-07 Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR...
GlobeNewswire 2022-03-25 ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corpo...
GlobeNewswire 2022-03-16 Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
GlobeNewswire 2022-03-15 ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer
GlobeNewswire 2022-03-14 Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million
GlobeNewswire 2022-03-08 Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NU...
GlobeNewswire 2022-03-02 Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, ...
GlobeNewswire 2022-03-01 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 2022-02-01 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 2022-01-03 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 2021-12-16 China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment o...
GlobeNewswire 2021-12-01 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 2021-11-10 Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
GlobeNewswire 2021-11-08 Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
GlobeNewswire 2021-11-04 Athenex Provides Third Quarter 2021 Corporate and Financial Update